Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsOutpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklistsIn vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pHPublic reporting improves antibiotic prescribing for upper respiratory tract infections in primary care: a matched-pair cluster-randomized trial in ChinaWSES consensus conference: Guidelines for first-line management of intra-abdominal infections.Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) databaseDaptomycin: pharmacology and clinical use.Current use of daptomycin in cardiac surgery and postoperative intensive care.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program.Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.Infusion-related reaction following daptomycin two-minute rapid intravenous administration.Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial).Daptomycin serum levels in critical patients undergoing continuous renal replacement.Administration interval and daptomycin toxicity: a case report of rhabdomyolysis.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.
P2860
Q26752922-D8F77FFD-0A32-4FE3-863D-D34BFDC5623EQ28088622-201281CA-1303-4F2B-B2C9-D12C8971BFB4Q28488311-9F5CD503-73E6-4F15-AA44-B7948265BB4CQ34340480-F43A2476-0363-44AC-A871-76A028AEE6E1Q34541183-43EED250-8BA7-460F-828C-14628FA3C698Q36929393-1F13EA46-5398-45E9-B6CF-342788389F3EQ37693931-D81A8FE4-EBED-49EC-846E-AEE62CDCBD80Q38086339-C8C59833-CDF6-49F5-8DD8-E080AC55C4BAQ38115356-7B7BC601-00C3-4FF7-ACF8-378B5F19B4F4Q38118211-88BC3A43-BACD-4BB9-862D-AB7C1CED4C0EQ38164685-139916AB-4CDB-456F-BEC6-9244E7B517D5Q38283514-45B3A617-8DF1-4833-BFA7-D22E79E0FE98Q40461222-F80A5549-63FC-4F72-BBF0-B0E696561EBBQ42285206-19BF986D-4914-4598-BA85-9736CD9A7CF2Q42751892-E4653055-F2E2-4D2C-9DF3-1F3C7729ECF0Q48197188-EB370E90-CA09-4D78-8F29-7EC3D575FF59
P2860
Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of the pharmacokine ...... in infusion or 2 min injection
@en
Comparison of the pharmacokine ...... n infusion or 2 min injection.
@nl
type
label
Comparison of the pharmacokine ...... in infusion or 2 min injection
@en
Comparison of the pharmacokine ...... n infusion or 2 min injection.
@nl
prefLabel
Comparison of the pharmacokine ...... in infusion or 2 min injection
@en
Comparison of the pharmacokine ...... n infusion or 2 min injection.
@nl
P2093
P2860
P356
P1476
Comparison of the pharmacokine ...... in infusion or 2 min injection
@en
P2093
Abhijit Chakraborty
Juergen Loeffler
Ricardo L Chaves
Sandip Roy
P2860
P304
P356
10.1093/JAC/DKP155
P407
P577
2009-04-22T00:00:00Z